Some of the key therapies for asthma treatment include GSK3511194 (depemokimab), MRx-4DP0004, AZD5718, CBP-201, Budesonide/salbutamol, Epinephrine intranasal spray, SM17, Quisovalimab, Amlitelimab, AZD8630, Ifetroban Oral Capsule, GDC-6599, and others. Leading asthma companies such as GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., and others are developing novel asthma drugs that can be available in the asthma market in the coming years. Asthma affected an estimated 262 million people in 2019 and caused 455K deaths.
Key Takeaways from the Asthma Market ReportĪs per DelveInsight analysis, the asthma market is expected to grow positively at a significant CAGR during the study period (2019–2032).Īccording to the WHO (2022), asthma is a major non-communicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children.
New York, USA, Ma(GLOBE NEWSWIRE) - Asthma Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - GlaxoSmithKline, AstraZeneca, 4D Pharma plc, Suzhou Connect Biopharmaceuticals, and OthersĭelveInsight’s Asthma Market Insights report includes a comprehensive understanding of current treatment practices, asthma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM. According to DelveInsight's’ estimates, the asthma market in 7MM is expected to show good positive growth, during the forecast period (2023–2032), mainly attributed to increasing prevalence, current therapies, and new product launches in the market.
0 kommentar(er)
